Abstract
The 2nd Next Generation Rotavirus Vaccine Developers Meeting, sponsored by PATH and the Bill and Melinda Gates Foundation, was held in London, UK (7–8 June 2022), and attended by vaccine developers and researchers to discuss advancements in the development of next-generation rotavirus vaccines and to consider issues surrounding vaccine acceptability, introduction, and uptake. Presentations included updates on rotavirus disease burden, the impact of currently licensed oral vaccines, various platforms and approaches for next generation rotavirus vaccines, strategies for combination pediatric vaccines, and the value proposition for novel parenteral rotavirus vaccines. This report summarizes the information shared at the convening and poses various topics worthy of further exploration.
Funder
Bill & Melinda Gates Foundation
Subject
Virology,Infectious Diseases
Reference52 articles.
1. GBD Collaborators (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet, 396, 1204–1222.
2. (2022, June 24). Immunization, Vaccines and Biologicals, Available online: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/rotavirus.
3. Effect of human rotavirus vaccine on severe diarrhea in African infants;N. Engl. J. Med.,2010
4. Effectiveness of Monovalent Rotavirus Vaccine After Programmatic Implementation in Botswana: A Multisite Prospective Case-Control Study;Clin. Infect. Dis.,2016
5. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: A randomised, double-blind, placebo-controlled trial;Lancet,2010